IVF vs ICSI — What the Difference Is, and When ICSI Actually Helps (2026)

Neither is better in general. ICSI is the right choice when sperm cannot reliably fertilise an egg on their own — a significant male factor, surgically retrieved sperm, frozen eggs, or a previous cycle in which fertilisation failed. When the male partner's sperm count and motility are normal, three large randomised trials found no significant difference in the chance of a baby, and NICE, ASRM and ESHRE all advise against using ICSI routinely.

So the useful question is not which technique is superior, but whether there is a specific reason for ICSI in your cycle. The rest of this page is about answering that.

In conventional IVF, eggs and prepared sperm are placed together in a dish and fertilisation happens on its own. In ICSI (intracytoplasmic sperm injection), an embryologist picks a single sperm and injects it directly into each mature egg.

Everything before and after that step is the same: the stimulation injections, the scans, egg collection under sedation, embryo culture and transfer. The difference happens in the laboratory over a few hours, and nothing about your day tells you which one was used.

One practical difference does reach you. Only mature eggs can be injected, so the number of eggs used for ICSI can be lower than the number collected, while in conventional IVF the whole batch is exposed to sperm. The two fertilisation rates are therefore counted from different starting points, which is worth knowing when a number is reported back to you.

Our pages on IVF and ICSI describe each procedure step by step.

ICSI was developed for male factor infertility, where too few competent sperm are available for conventional insemination to work. NICE's 2026 fertility guideline (NG257) sets out when to use it:

• Offer ICSI when sperm have been surgically retrieved, or when frozen-thawed eggs are being used (1.50.1)
• Consider ICSI when semen parameters are abnormal, taking into account how severe the abnormality is (1.50.2)
• Consider ICSI when a previous IVF cycle produced failed or very low fertilisation (1.50.2)

ASRM's 2026 committee opinion adds one more: ICSI may help in PGT-M cycles, where embryos are tested for a known single-gene condition, because it avoids stray sperm contaminating the test. In India, section 25 of the ART (Regulation) Act 2021 allows embryo testing only for known heritable or genetic disease, which is exactly that situation.

In each of these cases there is a named obstacle that ICSI removes. If one can be named in yours, the recommendation is doing what the technique was built for. Our guide to IVF with male factor infertility covers those situations in more depth.

No, on the best evidence available. Three randomised trials have compared the two techniques head to head in couples without a significant male factor:

• Vietnam, 2021 (Dang, Lancet): 1,064 couples with normal sperm count and motility. Live birth after the first transfer was 35% with ICSI and 31% with conventional IVF — risk ratio 1.11 (0.93 to 1.32), p=0.27.
• China, 2024 (Wang, Lancet): 2,387 couples with non-severe male factor across ten centres. Live birth after the first transfer was 33.8% with ICSI and 36.6% with conventional IVF — adjusted risk ratio 0.92 (0.83 to 1.03), p=0.16.
• Denmark, 2025 (Berntsen, Nature Medicine): 824 women in a first IVF cycle. Cumulative live birth from all fresh and frozen transfers was 43.2% with ICSI and 47.3% with conventional IVF — risk ratio 0.91 (0.79 to 1.06).

The point estimates fall on both sides of no effect and none is statistically significant. The 2023 Cochrane review, which predates the Chinese and Danish trials, reached the same verdict from the earlier randomised data: neither method superior, at low certainty.

Large registries lean slightly towards conventional IVF. Across 140,252 Canadian retrievals, cumulative live birth per retrieval was 38.5% with conventional IVF and 36.3% with ICSI. In US cycles without male factor (n = 317,996), live birth per cycle was 39.2% with conventional IVF and 36.5% with ICSI. An Australian cohort of 14,693 women found no significant difference in the non-male-factor group. Registries cannot fully separate the technique from the reasons it was chosen, so the honest summary is no demonstrated benefit — rather than a demonstrated harm.

These are the commonest reasons given for ICSI without a male factor, and ASRM's 2026 committee opinion addresses each. It concludes that ICSI is not recommended, in the absence of male factor, for:

• Unexplained infertility — it may reduce outright fertilisation failure in some studies, but has not been shown to improve live birth
• Low egg numbers or diminished ovarian reserve
• Advanced maternal age
• PGT-A (chromosome screening of embryos), where it has not improved live birth, euploidy or embryo numbers

ESHRE's 2023 recommendations on treatment add-ons reach the same place: "ICSI is not recommended for non-male factor infertility."

Not on its own. A secondary analysis of the Vietnamese trial asked whether the share of normally shaped sperm picks out couples who do better with ICSI. Across all 1,064 couples the median was 3% normal forms (interquartile range 1% to 6%) — below WHO's 4% reference limit, as it often is.

No interaction was found between morphology and the effect of ICSI on live birth, ongoing pregnancy, clinical pregnancy or total fertilisation failure (p = 0.181, 0.153, 0.168 and 0.788). The authors note the analysis may be underpowered at the extremes.

If you are looking at a morphology figure on your own report, our guide to reading a semen analysis report explains what the limit does and does not mean, and preparing for the test covers why a single result should not settle the question.

For the pregnancy itself, the trials are reassuring. The 2023 Cochrane review found probably little or no difference between ICSI and conventional IVF in multiple pregnancy, ectopic pregnancy, pre-eclampsia and prematurity, and ESHRE describes perinatal outcomes as appearing comparable.

For the child, there is one open question. ASRM's 2026 opinion states that ICSI "has been associated with a small increased risk of birth defects in offspring", and that it is unclear whether this applies when ICSI is used without a male factor, since men with poor semen carry more genetic abnormalities themselves. The Danish trial, which did look at couples without severe male factor, found no significant difference in congenital anomalies between the groups.

That is not a reason to fear ICSI when it is indicated. It is one more reason not to add it when it brings no benefit.

Because its use stopped tracking the problem it was built for. US national data (n = 1,395,634 fresh cycles) show ICSI use among cycles without male factor rising from 15.4% in 1996 to 66.9% in 2012. European registry data show ICSI going from 35% of all ART cycles in 1997 to over 70% in 2018, against a stable incidence of male factor infertility.

The usual justification is insurance against total fertilisation failure. ASRM puts a number on it from the 2001 UK trial: 33 couples would need ICSI to prevent one case of fertilisation failure with conventional insemination. That is a defensible trade when sperm are borderline, and much harder to defend as a policy for everyone.

ICSI also takes more laboratory work: 74.0 minutes on average in that trial against 22.9 minutes for conventional IVF.

We could not find a verified, published figure for what ICSI adds to an Indian IVF bill. What is published is the cost of the cycle as a whole.

An ICMR-NIRRCH study (PLoS One, 2026; n = 148 couples at five tertiary hospitals) found mean out-of-pocket spending per IVF cycle of ₹1,10,104 in public hospitals and ₹2,30,668 in private ones, with drugs making up 55% of the total. Only 5% of the 148 couples had insurance cover.

For scale, ESHRE cites a Dutch costing in which ICSI made treatment 8.3% more expensive than conventional IVF. Prices in India will differ, so ask your clinic for the ICSI line in writing.

ICSI and IVF are both assisted reproductive technology under section 2(1)(a) of India's ART (Regulation) Act 2021, so either must be done at a clinic registered under the Act (section 15), and only after written informed consent (section 22). The planning appointment, before that consent is signed, is the time to ask:

• What specific finding makes ICSI the recommendation for us — which semen result, on how many samples?
• Was there failed or very low fertilisation in a previous conventional cycle?
• What is your fertilisation rate with conventional IVF in cases like ours?
• What does ICSI add to the cost of this cycle?

A clear answer names something. "We use ICSI for everyone" is a clinic policy, not a finding about you; it may have reasons behind it, but you are entitled to hear them.

Being told a sperm problem is the reason for ICSI can land heavily on the male partner. It is a decision about how eggs and sperm are brought together in the lab, not a verdict on anyone. And if an earlier cycle used ICSI without a clear reason, the differences in the trials are small: that cycle was not wasted, and the point of knowing this is the next decision, not the last one.

If the semen analysis has not been repeated, that usually comes first. For the steps of a full cycle, see our guide to how an IVF cycle runs.